Financial Daily from THE HINDU group of publications
Tuesday, Dec 09, 2003
Financial Daily from THE HINDU group of publications Tuesday, Dec 09, 2003 |
|
|
|
|
|
Corporate
-
Announcements Industry & Economy - Health Ranbaxy's Augmentin gets US clearance Our Bureau
New Delhi , Dec. 8 RANBAXY Laboratories Ltd (RLL) has received the final approval from the US regulatory authorities to manufacture and market the bio-equivalent version of the antibiotic Augmentin in its chewable form. GlaxoSmithKline is the original patent holder for Augmentin. According to a Ranbaxy communiqué, issued here on Monday, the Division of Bioequivalence has determined Ranbaxy's Amoxicillin and Clavulanate Potassium Tablets USP (Chewable) in the strengths 200 mg/28.5 mg (base) and 400 mg/57 mg (base), to be bioequivalent and, therefore, therapeutically equivalent to the listed drug Augmentin{logicalnotshy} chewable tablets, 200 mg and Augmentin chewable tablets, 400 mg, respectively of GlaxoSmithKline. Total market sales of all forms of Amoxicillin and Clavulanate Potassium chewable tablets are estimated to be around $31.4 million.
Article E-Mail :: Comment :: Syndication
|
Stories in this Section |
|
The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription Group Sites: The Hindu | Business Line | The Sportstar | Frontline | The Hindu eBooks | Home |
Copyright © 2003, The
Hindu Business Line. Republication or redissemination of the contents of
this screen are expressly prohibited without the written consent of
The Hindu Business Line
|